// App-Quantinova.ai

4102 : Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) with pharmacokinetic (PK) and biomarker correlates.

Researchers

Presenter

  • Robin Katie Kelley

Principal Investigators

  • Halla Sayed Nimeiri

  • Pamela N. Munster

  • Madelyn Luttgen

  • Peter Kuhn

  • Yong Huang

  • Al Bowen Benson

  • Alan Paul Venook

  • Mary Frances Mulcahy

  • Maxwell Thomas Vergo

  • Amanda DeSon

  • Christi Murphy

  • Benjamin M. Yeh

  • Andrew H. Ko

  • Wolfgang Michael Korn

  • Jimmy Hwang

Medical Centers

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of California, San Francisco, Drug Studies Unit, South San Francisco, CA

  • University of California, San Francisco, San Francisco, CA

  • Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Northwestern University, Chicago, IL

  • Scripps Research Institute, La Jolla, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

  • N-Acylethanolamine acid amidase

  • Circulating tumor cells

Drug/Treatment

  • Temsirolimus

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved